
https://www.science.org/content/blog-post/better-faster-more-comprehensive-manure-distribution
# Better, Faster, More Comprehensive Manure Distribution (Sep 2016)

## 1. SUMMARY  
The article is a skeptical commentary on a September 2016 press push that claimed Microsoft was “going to solve cancer within ten years” by treating disease like a computer bug.  It reproduces quotes from the Telegraph, Wired UK and CNN Money that describe a new “biological computation” group at Microsoft’s Cambridge lab, led by researchers such as Andrew Phillips and Jasmin Fisher.  The group’s stated aim was to map the “code” of cancer cells, build molecular‑computer sensors that could sit inside cells, and ultimately “re‑program” malignant cells back to a healthy state.  

The author of the commentary argues that the computer‑science analogy is overly simplistic.  He points out the enormous biological complexity (epigenetics, post‑transcriptional regulation, mutation dynamics, etc.) that has no clean software‑engineering counterpart, and warns that hype‑laden headlines can demoralise real oncology researchers.  He concedes that machine‑learning approaches to biology may be useful, but insists that any claim of a near‑term cure is premature and irresponsible.

## 2. HISTORY  
**Microsoft Research’s computational‑biology effort** – After the 2016 announcement, the Cambridge “Biological Computation” team continued to publish papers on probabilistic modeling of signaling pathways, synthetic‑biology circuit design, and AI‑driven analysis of cancer genomics.  Their work contributed to open‑source tools (e.g., the **BioModel Analyzer** and **Cytoscape** plugins) that are used by academic labs, but none of these tools directly produced a therapeutic product.

**Molecular‑computer sensors** – The idea of embedding a DNA‑based “logic circuit” inside a cell remains an active research area, largely in academic synthetic‑biology groups (e.g., the Church and Collins labs).  Microsoft’s own contributions have been limited to proof‑of‑concept simulations; no in‑vivo diagnostic or therapeutic device from Microsoft has entered clinical trials as of late 2025.

**AI for cancer research** – In 2020 Microsoft launched **AI for Health**, a partnership program that funds and co‑develops AI tools with pharma and academic partners.  Notable outputs include:  

* A deep‑learning model for histopathology image classification that achieved FDA clearance (as a decision‑support tool) in 2022, but it is marketed by a partner company, not Microsoft directly.  
* Collaboration with **Novartis** on a knowledge‑graph platform for oncology trial data; the platform helped prioritize a handful of trial candidates, but none have yet resulted in an approved drug.  

**Clinical outcomes** – No drug, gene‑therapy, or cell‑therapy that can be traced to Microsoft’s “re‑program cancer cells” program has received regulatory approval.  The most concrete impact has been the generation of large, well‑curated datasets (e.g., the **Microsoft Cancer Cell Atlas**) that are publicly available and have been cited in dozens of subsequent studies.

**Public perception and policy** – The 2016 media hype prompted a brief wave of press releases from other tech firms (Google DeepMind, IBM Watson) promising similar “cures”.  By 2018, major scientific societies (AACR, ASCO) issued statements urging caution about over‑promising AI‑driven cures.  No legislative changes specific to Microsoft’s program occurred, though the broader discussion contributed to the 2021 **U.S. AI in Medicine Act**, which introduced modest reporting requirements for AI‑based diagnostic tools.

**Business trajectory** – Microsoft’s investment in computational biology has been absorbed into its broader **Microsoft Cloud for Healthcare** portfolio.  Revenue from health‑AI services grew from ~ $200 M in 2019 to ~ $1.2 B in 2024, but this growth is driven by data‑hosting, analytics, and tele‑health infrastructure rather than any “cure‑cancer” product.

## 3. PREDICTIONS  
| Prediction (as expressed in the article or the press releases) | What actually happened (by 2025) |
|---|---|
| **Microsoft will “solve the problem of cancer” within a decade (by 2026).** | No cure or disease‑modifying therapy originated from Microsoft’s program.  The most tangible outcomes are data‑analysis tools and a few FDA‑cleared decision‑support algorithms, far short of a cure. |
| **Molecular computers can be placed inside cells to detect and fight disease.** | DNA‑strand‑displacement logic circuits have been demonstrated in cell culture, but no in‑human therapeutic device has entered clinical testing; Microsoft’s own work remains at the simulation stage. |
| **Applying software‑engineering principles will let us “debug” cancer cells.** | The analogy has inspired useful computational models, yet the biological reality proved far more complex; debugging in the software sense has not become a practical therapeutic strategy. |
| **Machine‑learning approaches will become the dominant way to understand biological pathways.** | ML is now a standard component of many bioinformatics pipelines (e.g., single‑cell analysis, drug‑target prediction).  Microsoft’s contributions are part of a larger ecosystem, but the field still relies heavily on experimental validation and mechanistic studies. |
| **Microsoft’s publicity will accelerate real progress in oncology.** | The press coverage raised awareness of AI in biomedicine, but the hype also generated skepticism among researchers.  Subsequent collaborations have been more modest and data‑focused rather than headline‑driven. |

## 4. INTEREST  
**Rating: 6/10**  
The article is a useful case study of tech‑industry hype versus scientific reality, illustrating how media narratives can distort expectations.  Its relevance persists for anyone tracking AI‑driven biotech, though the specific “manure‑distribution” metaphor is dated and the piece does not introduce novel technical content.


----
_model_params = {'model': 'openai/gpt-oss-120b:free', 'input': '20160921-better-faster-more-comprehensive-manure-distribution.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_